Clinical and Experimental Ophthalmology. Vol.49, No.2 (2021), 203-211
Suggested Citation
Amy P. Jain, Pimkwan Jaru-Ampornpan, Raymond S. Douglas Thyroid eye disease: Redefining its management—A review. Clinical and Experimental Ophthalmology. Vol.49, No.2 (2021), 203-211. doi:10.1111/ceo.13899 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78407
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Thyroid eye disease: Redefining its management—A review
Thyroid eye disease (TED) is a debilitating, vision threatening disease that dramatically alters patients' quality of life. Until recently, the management of TED is a long arduous course with supportive therapy, followed by an extensive surgical treatment plan to reverse the disease endpoints. Teprotumumab offers an early, safe therapeutic intervention to help reverse disease end points such as diplopia and proptosis and improve quality of life.
